The Dynamic Media, Sera and Reagent Market in Biotechnology

Jul 2010| BIO014F| BCC Publishing

Report Highlights

  • Total worldwide sales revenues for media, sera, and reagent used in the biotechnology were $2,546.2 million in 2010, and are expected to increase to more than $3800 Million in 2015, at a compound annual growth rate (CAGR) of 8.7%.
  • The largest biotechnology segments in 2010 were Reagents. All Reagents in Biotechnology will increase from $1,066.6 million in 2010 to nearly $1,850.4 million in 2015, at a compound annual growth rate (CAGR) of 11.6%.
  • Sales of Media will experience high growth. This market segment was worth $821.8 million in 2010 and will increase at a 8.6% compound annual growth rate (CAGR) to reach a value of $1,242.4 million in 2015.
  • Sales of Sera will experience moderate growth. This market segment was worth $31657.8 million in 2010 and will increase at a 3.3% compound annual growth rate (CAGR) to reach a value of $772.5 million in 2015.


BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for media, sera, and reagents used in biotechnology. The key objective is to present a comprehensive analysis of the current market and its future direction for the next 5 years.
The improvisation of the market, the setbacks, and the needs of the market are discussed in this report. The types of cell culture and the products from cell culture technology are also portrayed. Also covered are the advantages and disadvantages of the use of various types of media.
A detailed analysis of the structure of the cell culture industry has been conducted. This includes the biotechnology reagents, media, and the sera used. Revenues are broken down by region. Sales figures are estimated for the 5-year period from 2010 through 2015.
Applications for the cell culture industry—media, sera, and reagents used in biotechnology—are also discussed separately, with an emphasis on the usage in the research, production, and contract segments. This report also covers significant patents and their allotments in each category.
Demand for cell culture products, namely, media, sera, and reagents, is increasing with the increasing demand for biopharmaceuticals. Cell culture, a crucial component of the life-sciences industry has witnessed major developments in the past three decades. Research and development (R&D) spending, along with increasing competition, patent expiries, new technologies, and an international marketplace are pointing this market in a new direction. During the evolution of cell culture technologies, a number of disciplines, such as cell biology, genetic engineering, protein chemistry, genomics and chemical engineering, have been successfully incorporated into the cell culture field.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of types of media used in light of the new technologies, growing competition, and changing customer needs.
This study contributes to the areas of market growth in the cell culture industry from the point of view of manufacturers and users. Biotechnological companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals, and research institutes will find this study to be of interest.
The scope of this study encompasses the biotechnology, pharmaceutical, and medical markets. BCC analyzes each market and its applications by its need for development of new medications through cell culture techniques, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.
Both primary and secondary research methodologies were used in preparing this market research report. BCC conducted a comprehensive search of the literature, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical/chemical/pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were contacted to obtain data for this study. Included were manufacturers and end users of biopharmaceutical and pharmaceutical companies through their production, research, and contract manufacturing/research lines. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
Shalini S. Dewan holds a master’s degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen to 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems: New Developments, New Technologies; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; andThe Dynamic Media, Sera and Reagent Market in Biotechnology. 
BCC offers an online information retrieval service. BCC’s home page, located at, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Frequently Asked Questions (FAQs)

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesMember Price
Full Report: The Dynamic Media, Sera and Reagent Market in Biotechnology145Free
Chapter- 1: INTRODUCTION3Free
Chapter- 3: OVERVIEW25Free
Chapter- 7: MARKETS31Free
Chapter- 8: END USERS11Free
Chapter- 9: PATENT ANALYSIS8Free
Chapter- 11: C. CRAMER & CO. GMBH15Free
Published - Mar-2007| Analyst - Shalini Shahani Dewan| Code - BIO014E

Report Highlights

  • The total U.S. sales of media, sera, and reagents for biotechnology was $979 million in 2005 and almost $1.1 billion in 2006. At a compound annual growth rate (CAGR) of 8.9%, this market will grow to reach more than $1.6 billion in 2011.
  • Sera will grow much more slowly in the market. This particular sector was worth $338.5 million in 2006 and will reach $401 million by 2011, a CAGR of just 3.5%
  • Reagents have the greatest potential for growth, worth $382 million in 2006 and growing at a CAGR of 12.8% to reach almost $700 million by 2011.
Published - Oct-2003| Analyst - Shalini Shahani Dewan| Code - BIO014D

Report Highlights

  • The market for media, sera and reagents in U.S. is estimated at $915.6 million in 2003. The market is expected to rise at an AAGR (average annual growth rate) of 13.1% and reach $1.7 billion by 2008.
  • U.S. sales for media are expected to reach $282.3 million in 2003 and $452.5 million in 2008, an AAGR of 9.9%.
  • The sera market, although slow, is rising at an AAGR of 3.5% and will reach $352.1 million in 2008 from $296.0 million in 2003.
  • The reagent market in 2003 is estimated at $337.3 million and is expected to rise at an AAGR of 21.5% and reach $892.6 million by 2008.
  • The reagent segment is the fastest growing, due to increases in expenditures for cell cultures. Ten to 12 new biological response modifiers are coming to market every year.

Published - Sep-2000| Analyst - Sanker Usha| Code - BIO014C

Report Highlights

  • The U.S. cell culture media market has been growing at a surprisingly fast pace since the last edition of this report, and some of the media suppliers are enjoying a growth rate higher than the overall rate. The U.S. market for cell culture media was estimated to be about $169.5 million in 1999. This is projected to grow to $190.2 million in 2000, and to reach $343.7 million in the year 2005. The estimated average annual growth rate is projected to be about 12.5%.
  • The sera portion of the U.S. market was an estimated $173.9 million in 1999. It should grow to $183.2 million by 2000, and $238.4 million by 2005. The average growth rate is expected to be 5.4% per year throughout this period.
  • The U.S. market for reagents used in cell culture was an estimated $151.7 million in 1999. This should grow to $170.4 million by 2000, and to $315.1 million by 2005. The average growth rate through this period is projected to be 13.0% per year.

Market Research Report

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries